Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9573 posts found.

Gilenya

Novartis looks to new measure of Gilenya outcomes

October 8, 2015 Research and Development fingolimod, gilenya, multiple sclerosis, relapsing multiple sclerosis

Novartis says a new analysis from two Phase III trials reinforces the long-term efficacy profile of its MS treatment Gilenya. …
News

UCB plots new Vimpat submissions after positive monotherapy results

October 8, 2015 Research and Development EMA, European Medicines Agency, UCB, carbamazepine, epilepsy, lacosamide, phase III, vimpat

A Phase III non-inferiority study comparing UCB’s Vimpat with carbamazepine suggests the two drugs can be used as monotherapy treatments.  …
News
Genzyme

Genzyme’s Lemtrada shows five-year efficacy in extended trials

October 8, 2015 Research and Development Genzyme, Lemtrada, MS, RRMS, alemtuzumab, multiple sclerosis, relapsing-remitting multiple sclerosis

Sanofi’s subsidiary Genzyme has achieved positive data from an extension study of Lemtrada in patients with relapsing remitting multiple sclerosis …
News
Nobel Prize

Infectious diseases dominate Nobel Prize awards for medicine

October 8, 2015 Manufacturing and Production, Research and Development Nobel Prize, artemisinin, ivermectin, malaria, mectizan, river blindness

Pharma researchers have been awarded the 2015 Nobel Prize for their work on a river blindness treatment, along with work …
News
ms_symptoms

Multiple Sclerosis treatment will be a $20bn market by 2024

October 7, 2015 Research and Development multiple sclerosis

The value of the multiple sclerosis therapeutics market will rise slowly from $17.2 billion in 2014 to approximately $20 billion …
News
ms_early_intervention

Experts call for greater urgency in MS treatment

October 7, 2015 Research and Development multiple sclerosis

A therapeutic strategy in multiple sclerosis (MS) that aims to maximise lifelong brain health (neurological reserve) needs to be widely …
News
ferring_president

PROFILE: Ambitious Ferring wants to be global fertility leader

October 7, 2015 Manufacturing and Production, Research and Development Ferring, peptides

The stunning view of the Alps across Lake Geneva from Ferring’s corporate headquarters in Saint-Prex seems appropriate for a company …
Feature
amerisourcebergen

AmerisourceBergen acquires sterile compounder PharMEDium for $2.5bn

October 7, 2015 Research and Development, Sales and Marketing AmerisourceBergen, mergers and acquisitions

AmerisourceBergen will now source compounded drugs for its hospital clients by manufacturing them itself after spending more than $2.5 billion …
News
akabia_logo

Akebia passes vadadustat for anaemia phase III study with FDA & EMA

October 7, 2015 Research and Development Akabia, FDA, anaemia

Akebia Therapeutics has announced the successful completion of the End-of-Phase II Meeting process with the FDA and the Scientific Advice …
News
joachim_hoeltz

Rondo AG appoints Joachim Hoeltz as chief exec

October 7, 2015 Manufacturing and Production, Research and Development, Sales and Marketing

Joachim Hoeltz has been appointed chief executive at pharmaceutical packaging company Rondo AG within the Business Area Medipak Systems. He …
Appointment
merckincweb

NICE approves Merck’s Keytruda for advanced skin cancer following ipilimumab treatment

October 7, 2015 Research and Development Merck, NHS, NICE, keytruda, skin cancer

The National Institute for Health and Care Excellence (NICE) has approved Merck’s Keytruda (pembrolizumab) for treating advanced skin cancer after …
News
aubagio

Sanofi MS treatment Aubagio slows brain atrophy in Phase III trial

October 7, 2015 Research and Development Genzyme, MS, Sanofi

Sanofi and its subsidiary Genzyme have announced that magnetic resonance imaging (MRI) data from the Phase III TEMSO study demonstrate …
News
aristada

FDA approves Alkermes schizophrenia treatment

October 6, 2015 Research and Development Alkermes, Aristada, FDA, schizophrenia

The US Food and Drug Administration (FDA) has approved Alkermes’s Aristada (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia. Aristada …
News
flu_vaccien_smaller

Flu jab reduces risk of stroke for two months

October 6, 2015 Research and Development flu vaccine, stroke

The risk of suffering a stroke is significantly reduced for up to two months after receiving a flu vaccine, a …
News
oral_insulin

Moving forward in diabetes

October 6, 2015 Research and Development Novo Nordiak, diabetes

As many as 387 million people worldwide are living with diabetes, and it is predicted that by 2035 more than …
Feature
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025